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Abstract
Background: Late-onset Pompe disease (LOPD) is a rare, hereditary, progressive disorder that is usually
characterized by limb-girdle muscle weakness and/or respiratory insufficiency. LOPD is caused by mutations in the
acid alpha-glucosidase (GAA) gene and treated with enzyme replacement therapy (ERT).
Methods: We studied the clinical, brain imaging, and genetic features of the Belgian cohort of late-onset Pompe
disease patients (N = 52), and explored the sensitivity of different outcome measures, during a longitudinal period
of 7 years (2010–2017), including the activity limitations ActivLim score, 6 min walking distance (6MWD), 10 m walk
test (10MWT), MRC sum score, and forced vital capacity (FVC) sitting/supine.
Results: In Belgium, we calculated an LOPD prevalence of 3.9 per million. Mean age at onset of 52 LOPD patients
was 28.9 years (SD: 15.8 y), ranging from 7months to 68 years. Seventy-five percent (N = 39) of the patients initially
presented with limb-girdle weakness, whereas in 13% (N = 7) respiratory symptoms were the only initial symptom.
Non-invasive ventilation (NIV) was started in 37% (N = 19), at a mean age of 49.5 years (SD: 11.9 y), with a mean
duration of 15 years (SD: 10.2 y) after symptom onset. Brain imaging revealed abnormalities in 25% (N = 8) of the
patients, with the presence of small cerebral aneurysm(s) in two patients and a vertebrobasilar dolichoectasia in
another two. Mean diagnostic delay was 12.9 years. All patients were compound heterozygotes with the most
prevalent mutation being c.-32-13 T > G in 96%. We identified two novel mutations in GAA: c.1610_1611delA and
c.186dup11. For the 6MWD, MRC sum score, FVC sitting and FVC supine, we measured a significant decrease over
time (p = 0.0002, p = 0.0001, p = 0.0077, p = 0.0151), which was not revealed with the ActivLim score and 10MWT
(p > 0.05).
Conclusions: Awareness on LOPD should even be further increased because of the long diagnostic delay. The
6MWD, but not the ActivLim score, is a sensitive outcome measure to follow up LOPD patients.
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Introduction
Pompe disease, also known as glycogen storage disease type
2 (GSD2) or acid maltase deficiency, is an autosomal reces-
sive disorder caused by a deficiency of the lysosomal en-
zyme acid alpha-glucosidase (GAA), resulting in the
accumulation of glycogen in muscle cells. This usually leads
to progressive limb-girdle muscle weakness and respiratory
insufficiency, but heart, liver and the nervous system can
also be affected [1–5]. Depending on the residual GAA en-
zyme activity, the disease either develops during the first
months of life as the classic infantile Pompe disease (IOPD)
[6], or later in life (childhood, adolescence or adulthood)
with a milder phenotype known as late-onset Pompe dis-
ease (LOPD) [3]. Glycogen storage disease type 2 is a rare
disorder, with an estimated prevalence of 1:283,000 in Eur-
ope [7]. Over 200 different mutations in the GAA gene have
been described so far [8]. Current treatment consists of en-
zyme replacement therapy (ERT), which is reimbursed in
Belgium since 2006 [9, 10], and supportive therapies such
as (non-)invasive ventilation and physiotherapy. Similar to
many other neuromuscular disorders, validated outcome
measures are largely lacking in Pompe disease.
Here, we studied the clinical, brain imaging, and gen-
etic features of the Belgian cohort of LOPD patients
(N = 52), and the sensitivity of different outcome mea-
sures, during a longitudinal period of 7 years (2010–
2017). One of the outcome measures was the activity
limitations measure ActivLim [11–13], which has been
evaluated previously in several other neuromuscular dis-
orders, but not specifically in Pompe disease.
Patients and methods
LOPD patients
In this retrospective cohort study, we obtained pseudo-
nymized data from LOPD patients from the seven
neuromuscular reference centres in Belgium, where all
the known LOPD patients are followed (N = 52), and
from the Pompe disease registry (Sanofi-Genzyme). For
patients receiving ERT in Belgium, a regular 6-month
standardised follow-up and inclusion in a neuromuscular
reference centre is mandatory. This allowed us to collect
reliable data. We gathered the following patient data:
gender, current age, age at onset, symptoms at onset,
current disease stage, gene mutations, age at start of
ERT, (non)-invasive ventilation and start-up age, serum
creatine kinase (CK) (normal value for males < 190 U/l,
females < 174 U/l), brain imaging either computed tom-
ography (CT) including CT-angiography or magnetic
resonance imaging (MRI) including MR-angiography.
Furthermore, we studied the following functional data in
the period between 2010 and 2017: forced vital capacity
(FVC) in sitting and supine position (percentage of the
predicted normal value), 6-min walk distance (6MWD),
10-m walk test (10MWT), Medical Research Council
(MRC) sum score (shoulder abduction, elbow flexion,
elbow extension, hip flexion, knee extension and knee
flexion on both sides; each muscle group is scored be-
tween 0 and 5, maximum total score is 60), and the
ActivLim (acronym of “ACTIVity LIMitations”) ques-
tionnaire [11–13] . The latter comprises 22 daily activ-
ities to be rated by the patients as impossible, difficult or
easy. It is a validated measure of daily activity limitations
for patients with neuromuscular diseases [14]. A higher
ActivLim score corresponds to a better functional level.
The ActivLim score was computed using the Rasch
model. Genetic analyses comprised both Sanger sequen-
cing and MLPA analysis to also detect deletions and du-
plications. The genetic results were compared with the
Pompe disease GAA variant database [8] and current lit-
erature [15].
Statistical analysis
We performed all statistical analyses using SAS software,
version 9.4 of the SAS System for Windows. A linear
mixed model with correlated random intercept and
slope was used to evaluate the evolution of each variable
as a function of the years since onset. Restricted cubic
splines with four knots [16] were used to allow nonline-
arity. Likelihood-ratio tests were used to test the as-
sumption of linearity, and to test if there was evidence
for a change over time (in the model assuming linearity,
as well as in the model allowing a nonlinear relation).
The same methodology was used to verify the relation
between the ActivLim score and each of the other vari-
ables. Thus, instead of using years since onset, the Activ-
Lim score functioned as predictor in the model. After
standardising the variables, the estimate of the slope in
the model assuming linearity was reported. This estimate
corresponds to a correlation coefficient. Note that this
coefficient quantifies the association within a subject. To
evaluate the cross-sectional correlation, which answers
the question if a patient with on average high ActivLim
values has also on average high values for another out-
come measure, mean values per subject have been calcu-
lated and the correlation based on these mean values
was reported.
Results
Prevalence of LOPD in Belgium
In Belgium, we identified 52 patients with LOPD, be-
longing to 48 families. The calculated prevalence of
LOPD in Belgium is 3.9 per million, on a current popu-
lation of 11,431,406 [7].
Demographic and clinical features of LOPD patients in
the Belgian cohort (Table 1)
Twenty-seven patients were female (52%), 25 male
(48%). Mean current age was 47.9 years (SD: 15.2 y; N =
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Table 1 Clinical, brain imaging and genetic features of the Belgian cohort of LOPD patients
ID Gender Current
age (y)
Current
disease
stage
Age at
symptom
onset (y)
Symptoms
at onset
Duration
of ERT (y)
Ventilation
(age at
startup in
y)
Brain imaging Year of
genetic
diagnosis
(age in
years)
GAA
mutation
1
GAA
mutation 2
1 F D D (68y) 42 LW 2 NIV (54y);
invasive
(68y)
ND 2013 (65y) c.-32-13
T > G
c.2219_
2220del
2 F 66 A 58 R 4 NIV (58y) Normal (CT) 2014 (60y) c.-32-13
T > G
c.2331 + 2
T > A
3 F 23 A 14 LW 8 – ND 2010 (14y) c.-32-13
T > G
c.1564C > G
4 M 56 A 15 LW, F 13 NIV (39y) ND 2007 (44y) c.-32-13
T > G
c.258dupC
5 M 55 A 26 LW, F 2 NIV (53y) ND 2016 (52y) c.-32-13
T > G
c.2261dupC
6 F 65 A 13 LW 7 – ND 2012 (58y) c.-32-13
T > G
c.258dupC
7 M 44 A 14 LW, F 4 NIV (32y) ND 2007 (32y) c.-32-13
T > G
del exon 18
8 M D D
(age?)
10 R 3 invasive
(42y)
ND 2007 (41y) c.-32-13
T > G
c.956del7
9 F 75 W 49 LW 13 – Atrophy, mild
microvascular white
matter lesions (MRI)
2005 (61y) c.-32-13
T > G
c.525delT
10 M D D
(age?)
68 R 8 NIV (75y) ND NA c.-32-13
T > G
–
11 M 45 A 11 LW 13 NIV (37y) Normal (MRI) 2007 (33y) c.-32-13
T > G
c.1548G > A
12 M 27 A 7 LW 14 – ND 2002 (20y) c.-32-13
T > G
c.2331 + 2
T > A
13a F 45 A 36 LW 2 – ND NA c.-32-13
T > G
c.1115A > T
14
a
M D D (62y) NA R 2 NIV (58y) ND 2005 (60y) c.-32-13
T > G
–
15a M 55 A 30 R 13 NIV(36y) ND 2004 (40y) c.-32-13
T > G
del exon 18
16a M 59 A 52 NA 11 – Normal (MRI) 2004 (44y) c.-32-13
T > G
del exon 18
17 F 64 A 51 R, LW 9 – Normal (MRI) 2008 (53y) c.-32-13
T > G
c.258dupC
18 F 27 A 11 NA 12 – Normal (MRI) 2006 (14y) c.-32-13
T > G
c.258dupC
19 F 48 A 35 R, LW, AW 10 – Normal (MRI) 2008 (37y) c.-32-13
T > G
del exon 18
20 F 50 A 31 R, LW, AW 9 – Moderate
ventriculomegaly (MRI)
2009 (40y) c.-32-13
T > G
c.692 +
1G > T
21b M 50 A 20 R, LW, AW 10 – Normal (MRI) 2008 (39y) c.-32-13
T > G
c.1610_
1611delA
22b M 47 A 37 R, LW, AW 9 – Normal (MRI) 2008 (36y) c.-32-13
T > G
c.1610_
1611delA
23 M 34 A 15 NA 7 – Normal (MRI) 2007 (22y) c.-32-13
T > G
c.2608C > T
24 M 15 A 7 mo NA 12 – Aspecific T2
hyperintensity in right
thalamus (MRI)
2007 (3y) c.-32-13
T > G
del exon 18
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Table 1 Clinical, brain imaging and genetic features of the Belgian cohort of LOPD patients (Continued)
ID Gender Current
age (y)
Current
disease
stage
Age at
symptom
onset (y)
Symptoms
at onset
Duration
of ERT (y)
Ventilation
(age at
startup in
y)
Brain imaging Year of
genetic
diagnosis
(age in
years)
GAA
mutation
1
GAA
mutation 2
25 F 41 A 17 LW, R 8 – Normal (MRI) 2007 (29y) c.-32-13
T > G
c.1655 T > C
26 M 10 A 2.5 R, LW 6 – Normal (MRI) 2013 (4y) C.2608C >
T
c.1839G > C
27 F 59 A 43 R, LW, AW 5 – Normal (MRI) 2013 (53y) c.-32-13
T > G
c.2608C > T
28 F 35 A 28 R, LW, AW 3 – Normal (MRI) 2015 (31y) c.-32-13
T > G
c.1121G > A
29 F 23 A 9 mo LW 14 – Normal (MRI) 2000 (4y) c.-32-13
T > G
c.923A > C
30 M 63 A 39 R 13 NIV (40 y) Vertebrobasilar
dolichoextasia,
hypointensities in basal
ganglia (SWI) (MRI)
2007 (51y) c.-32-13
T > G
c.258dupC
31 F 50 A 35 LW 13 – Normal (MRI) 2007 (38y) c.-32-13
T > G
c.1548G > A
32 F 73 A 28 LW 13 – ND 2007 (61y) c.-32-13
T > G
c.1710C > G
and
c.1923G > A
33 F 63 A 44 LW 11 – Normal (CT) 2008 (52y) c.-32-13
T > G
del exon 18
34c M 68 A 45 LW, ptosis
left side
12 NIV (60 y) Aneurysm right
vertebral artery (MRI)
2007 (66y) c.-32-13
T > G
c.1681_
1699dup19
35c
a
F D D (78y) 44 LW, AW – NIV (72 y) Vascular
leukoencephalopathy
(CT)
2007 (72y) c.-32-13
T > G
c.1681_
1699dup19
36 M 47 A 25 LW 11 – Multiple small
aneurysms (right ACI
and left ACA) (MRI)
2008 (36y) c.-32-13
T > G
c.1075G > A
37d M 45 A 17 LW 10 – Normal (MRI) 2009 (35y) c.-32-13
T > G
c.482_
483del
38 F 41 A 27 HyperCK, F 9 – Normal (MRI) 2009 (31y) c.-32-13
T > G
c.525delT
39d F 49 A 42 LW 7 – Normal (MRI) 2011 (41y) c.-32-13
T > G
c.482_
483delCC
40 F 35 A 18 LW 3 – Normal (MRI) 2016 (32y) c.-32-13
T > G
c.2261dupC
41 M 55 A 42 LW 2 NIV (53 y) Normal (MRI) 2017 (53y) c.-32-13
T > G
c.2608C > T
42 M 59 A 51 LW 5 – ND 2014 (53y) c.-32-13
T > G
c.258dup
43 F 63 A 25 LW 11 – ND 2011 (54y) c.-32-13
T > G
c.186dup11
44 F 62 A 44 LW 7 – ND 2007 (51y) c.-32-13
T > G
c.1115A > T
45 F D D (65y) 44 LW, R 7 NIV (55y) Normal (CT) 2008 (57y) c.-32-13
T > G
c.701C > G
46 M 58 A 27 LW 8 NIV (54y) ND 2012 (51y) c.-32-13
T > G
c.258dup
47 M 53 A 29 LW 11 NIV (41y) Normal (CT) 2008 (42y) c.-32-13
T > G
c.525delT
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45), and mean age at symptom onset 28.9 years (range [7
mo – 68 y]; SD: 15.8 y). Two patients had onset of
symptoms below 1 year of age (7 and 9months); how-
ever, enzyme activity level and normal cardiac investiga-
tions were compatible with LOPD. In 75% of patients
(N = 39), limb-girdle weakness was the initial symptom
of the disease, presenting either as the only symptom or
in combination with other abnormalities such as respira-
tory weakness and/or axial weakness and/or fatigue. One
third (N = 17) of patients experienced respiratory prob-
lems as an initial symptom of the disease, and in 13%
(N = 7) respiratory symptoms were the only initial symp-
tom. In one patient, the disease presented with fatigue
and an increased serum CK-level. Currently, only one of
the 45 living patients is wheelchair-dependent, whereas
the others are still ambulatory (although some of them
use walking aids and/or a wheelchair for longer dis-
tances). Brain imaging (either CT of MRI) including im-
aging of the vessels was performed in 32 patients and
revealed abnormalities in eight patients (25%). Small
cerebral aneurysm(s) were detected in two patients and
a vertebrobasilar dolichoectasia in another two (Table
1).
All patients were treated with enzyme replacement
therapy (ERT), except one patient because of advanced
age and severe clinical stage at the time of ERT intro-
duction (patient 35, Table 1). Mean age at start-up of
ERT was 41.2 years (SD: 15.9 y) and mean duration of
ERT treatment up to now was 8.1 y (SD: 4.0 y). Nineteen
patients (37%) were treated with non-invasive ventilation
(NIV) starting at a mean age of 49.5 years (range [32–
75], SD: 11.9 y), with a mean duration of 15 years (SD:
10.2 y) after symptom onset. One of these patients sub-
sequently needed invasive ventilation at the age of 68
years, 14 years after starting NIV (patient 1, Table 1).
Another patient was treated immediately with invasive
ventilation at age 42 years, due to respiratory failure (pa-
tient 8, Table 1). Interestingly, this patient presented
with respiratory difficulties as a first symptom at age 10
years. Mean serum-CK levels prior to ERT were 686 U/l
(range [65–2246], SD: 510 U/l), whereas the current
mean serum-CK values (under ERT) were 399 U/l (range
[19–1303], SD: 326 U/l).
Diagnosis and genetic results in LOPD patients in the
Belgian cohort (Table 1)
In our cohort, all patients were compound heterozy-
gotes, none of them carried homozygous mutations in
GAA. The majority (49/51, 96%) harboured the frequent
c.-32-13 T > G (IVS1) mutation in the GAA-gene. We
identified a novel GAA mutation in three patients be-
longing to two different families: c.1610_1611delA (pa-
tients 21 and 22) and c.186dup11 (patient 43, Table 1).
In two patients, we identified only one mutation in
GAA, but we could not find a second mutation (patients
10 and 14, Table 1). However, the diagnosis in these pa-
tients was proven by reduced GAA enzymatic activity in
blood and muscle tissue. Mean age at genetic diagnosis
was 40.8 years (SD: 16.4 y), and diagnostic delay between
symptom onset and genetic diagnosis 12.9 years (range
[0–45], SD: 10.8 y).
Data on motor performances (6MWD, 10MWT, MRC sum
score), respiratory function (FVC) and ActivLim score in
LOPD patients
The last measured mean value for 6MWD was 385.1 m
(SD: 167.7), for 10MWT 9.2 s (SD: 6.9), for the MRC
sum score 49.7 (SD: 6.7), FVC sitting 73.8% (SD: 25.7)
Table 1 Clinical, brain imaging and genetic features of the Belgian cohort of LOPD patients (Continued)
ID Gender Current
age (y)
Current
disease
stage
Age at
symptom
onset (y)
Symptoms
at onset
Duration
of ERT (y)
Ventilation
(age at
startup in
y)
Brain imaging Year of
genetic
diagnosis
(age in
years)
GAA
mutation
1
GAA
mutation 2
48 M 46 A 9 LW 14 NIV (38y) Normal (MRI) 2007 (34y) c.1-45 T >
G
c.2608C > T
49 F 45 A 20 R 2 – Vertebrobasilar
dolichoextasia (MRI)
2017 (43y) c.-32-13
T > G
c.525delT
50 M 40 A 36 LW 3 NIV (37y) ND 2017 (38y) c.-32-13
T > G
c.1115A > T
51
a
F 21 A 18 LW, F 4 mo – ND 2019 (21y) c.-32-13
T > G
c.1548G > A
52 F D D
(age?)
NA NA NA (until
D)
NIV (49y) ND NA NA NA
A ambulatory; ACA anterior cerebral artery, ACI internal carotid artery, AW axial weakness, CT computed tomography, D deceased, ERT enzyme replacement
therapy, F female, F fatigue, GAA alpha-glucosidase gene, HyperCK increased creatine kinase in blood, LW limb-girdle weakness, M male, mo months, MRI magnetic
resonance imaging, NA not available, ND not done, NIV non-invasive ventilation, R respiratory weakness, SWI susceptibility weighted imaging, W wheelchair-
bound, y years. a, patients not included in statistical analysis of functional tests (ActivLim data lacking). Letters in superscript indicate corresponding family
members. New mutations are indicated in bold
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and FVC supine 57.3% (SD: 25.3). For the patients using
(non-)invasive ventilation (N = 19), mean FVC sitting
was 51.1% (SD: 24.8) and mean FVC supine 33.0% (SD:
15.5).
Longitudinal data on 6MWD, 10MWT, MRC sum score,
FVC sitting, FVC supine and ActivLim score were available
for 43, 41, 44, 48 and 33 out of 51 patients, respectively
(Fig. 1). Most observations were made during the first 25
years after disease onset: 195/222 (88%) for 6MWD, 182/
210 (87%) for 10MWT, 186/213 (87%) for MRC sum score,
and for FVC sitting 219/253 (87%), FVC supine 159/186
(85%) and ActivLim score 126/151 (83%). For some of the
outcome measures there seems to be an improvement ini-
tially, before deterioration becomes obvious. We calculated
the evolution over time (years after symptom onset) for the
different outcome measures (6MWD, 10MWT, MRC sum
score, FVC sitting and supine, ActivLim score). For the
6MWD, MRC sum score, FVC sitting and FVC supine, we
observed a significant decrease over time (p = 0.0002, p =
0.0001, p = 0.0077, p = 0.0151, respectively) (Fig. 2, Table 2).
For the ActivLim score, we observed a non-significant lin-
ear decrease over time (p = 0.0938). Excluding one outlier,
there was also no significant change for the 10MWT over
time (p > 0.05) (Fig. 2, Table 2).
Correlation of longitudinal motor and respiratory
outcome measures (6MWD, 10MWT, MRC sum score, FVC
sitting, FVC supine) with the ActivLim score
Two correlations were performed: a cross-sectional correl-
ation based on the mean values per subject (differences in
number of measurements were ignored as simplification)
and the within-subject correlation as derived from the
mixed model. For the 6MWD, there is a significant correl-
ation for the mean values per subject and the within-
subject measurements (p = 0.0005, p = 0.0018, respect-
ively). For the 10MWT, we also found significant correla-
tions for these two measures (p = 0.0010, p = 0.0001,
respectively), after exclusion of one outlier. For MRC sum
score there was a significant correlation when comparing
means per subject (p = 0.0240), but not within-subject
(p > 0.05). For FVC values, both sitting and supine, there
was a significant correlation when comparing means per
subject (p = 0.0082, p = 0.0044, respectively), but within-
subject only for supine FVC (p = 0.0346).
Discussion
LOPD is a rare disease and associated with a long
diagnostic delay
We established a prevalence of LOPD in Belgium of 3.9
per million or 1:256,000. An overall estimated preva-
lence of 1:283,000 has been reported in Europe [17, 18].
A cohort study in Austria revealed an even lower preva-
lence of 1:351,000 of Pompe disease (including both
LOPD and infantile forms) [18]. Thus, LOPD is a rare
disease, and the low prevalence may be one explanation
for the long diagnostic delay of almost 13 years in our
study, 7.4 years in the Austrian cohort [18], about 5 years
in a Chinese patient group [19] and 3.3 years in an Iran-
ian cohort [20]. Furthermore, the clinical presentation is
variable and can be mild and non-specific, especially at
the beginning of the disease. Some patients are pauci- or
asymptomatic and only present with hyperCKemia or fa-
tigue. Importantly, in 13% of our patients, respiratory
symptoms were the only initial symptom of the disease.
Early recognition and diagnosis of Pompe disease is im-
portant since treatment (ERT) is available and it has
been shown that ERT is more efficient in early disease
stages [9]. In later disease stages, patients with LOPD
mainly show limb-girdle and axial muscle weakness with
or without respiratory symptoms, which was also the
case in our study population. In order to decrease the
long diagnostic delay in LOPD patients, awareness on
LOPD as a rare disease should be significantly raised
further.
Cerebral (vascular) abnormalities in LOPD
Brain imaging (either CT or MRI) including imaging of the
vessels revealed abnormalities in 25% (N = 8) of the pa-
tients. Most anomalies were nonspecific findings but in two
patients small cerebral aneurysm(s) (2/32; 6.5%) were de-
tected and a vertebrobasilar dolichoectasia in another two
(2/32; 6.5%). Recent studies in LOPD showed a relative
higher prevalence of intracranial abnormalities than we
found in our study. Montagnese et al. [21] revealed the
presence of aneurysms in 9.5% of LOPD patients (2/21)
and a vertebrobasilar dolichoectasia in 47% (10/21). Musu-
meci et al. [22] also reported a higher prevalence of intra-
cranial aneurysms (3/21; 14%) and a vertebrobasilar
dolichoectasia (11/21; 52%) in LOPD patients. Furthermore,
in both studies a relatively high frequency of lacunar en-
cephalopathy was reported (62 and 57%, respectively).
Management guidelines for aneurysms and other intracra-
nial abnormalities in Pompe disease are lacking; mostly,
current general recommendations for surgery or for radio-
logical follow-up are used. As intracranial vascular anomal-
ies can lead to serious complications, performing brain
imaging (preferably MRI with MR angiography) in LOPD
patients, at least once at the time of diagnosis, is recom-
mended [23]. If aneurysms are detected and warrant no
treatment, brain imaging should be repeated every 6–12
months, as indicated by the guidelines of the American
Stroke Association for brain aneurysms in general [24].
The 6MWD, MRC sum score, FVC sitting and FVC supine
are sensitive longitudinal outcome measures in LOPD, in
contrast to the ActivLim score and 10MWT
Defining appropriate outcome measures is important to
understand the disease course and to better design
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current and future clinical trials in LOPD. We ob-
tained longitudinal data on distinct outcome measures
in our study population between 2010 and 2017, irre-
spective of age, clinical status, disease duration or
therapy duration. We studied both motor and respira-
tory parameters. FVC is measured both in sitting and
supine position, because diaphragmatic involvement,
which frequently occurs in LOPD, can be measured
by a significant difference of more than 25% between
the two FVC values. For the 6MWD, MRC sum
score, FVC sitting and FVC supine, we measured a
significant decrease over time in LOPD patients, even
though they were treated with ERT. This deterior-
ation was not revealed by the 10MWT and ActivLim
Fig. 1 Panels a through f show the individual data points of the mentioned outcome parameters over time (years since symptom onset). Panel a
6MWD (in meters); Panel b MRC sum score (maximum score of 60); Panel c and d FVC (% of predicted outcome); Panel e Activlim score; Panel f
10MWT (in seconds)
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score, although our data suggested a trend towards a
decline.
Vandervelde et al. [12] showed that in several other
neuromuscular diseases, such as Duchenne muscular
dystrophy, other muscular dystrophies and Charcot-
Marie-Tooth neuropathy, the ActivLim score was
possibly even more sensitive than patients’ self-
perception to report change in functional status (overall
better, stable or worse). In Batcho et al. [13], the Activ-
Lim score (analysed with the rating scale Rasch model)
was validated in a more heterogeneous group of neuro-
muscular disorders in the longitudinal monitoring of
Fig. 2 Panels a through f show the evolution of the mentioned outcome parameters over time (years since symptom onset), with the upper and
lower dotted lines indicating the 95% confidence interval. Dotted green line shows the expected linear evolution of each parameter over time.
Panel a 6MWD (in meters); Panel b MRC sum score (maximum score of 60); Panel c and d FVC (% of predicted outcome); Panel e Activlim score;
Panel f 10MWT (in seconds)
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functional status. However, these two studies did not in-
clude patients with LOPD. Van der Beek et al. [25] de-
veloped a Pompe-specific scale, i.e. the Rasch-built
Pompe-specific activity (R-PAct) scale. Difficulty of tasks
incorporated in different questionnaires differs substan-
tially between neuromuscular diseases; this could be one
reason why we do not find a significant change in the
ActivLim score in LOPD. In Lachmann and Schoser
[26], the minimally clinical important difference deteri-
oration in FVC in non-treated Pompe patients would
possibly be felt after 2 years, for the 6MWD this would
be 9 years. This might also be an explanation why there
is a change in some outcome measures, but not in the
ActivLim score.
Not all changes in outcome measurements in neuromus-
cular diseases result in a change in functionality [26], the
relation between motor function and activity level is not ne-
cessarily straightforward [27, 28]. Declines in walking dis-
tance, speed or forced vital capacity are not necessarily
clinically significant or even perceived as a decline by the
patient. Therefore, activity limitations should be assessed
separately in patients with neuromuscular diseases, but in
LOPD patients the ActivLim score may not be the best pa-
tient reported outcome measure to asses this.
When comparing mean values of respiratory function
and 6MWD, findings in our LOPD cohort are compar-
able to earlier described LOPD patient groups [10, 18,
29, 30]. In the Austrian cohort, 6MWD during ERT was
373.5 m [18], and Kuperus et al. [30] showed that the
median 6MWD changed from 376 to 416 m over a
period of 5 years following ERT onset. They measured
an increase in 6MWD during the first year after treat-
ment onset, and a decline from then on. In the meta-
analysis of Schoser et al. [10], where distances between
246 and 660 m were measured, the largest improvement
of the 6MWD was measured the first 20 months after
start of ERT. Similarly, in our cohort, the 6MWD de-
clined over the years, but we collected data irrespective
of ERT and of ERT duration.
The 6-min walk distance (6MWD) is most commonly
used to measure exercise capacity in LOPD [26, 31].
This capacity may be limited by multiple causes, such as
peripheral muscle weakness and respiratory function.
Furthermore, this may vary between patients. In Du-
chenne and Becker muscular dystrophy, as well as in
some pulmonary diseases, the 6MWD is a validated out-
come measure, often used in combination with other
tests, such as quantitative muscle MRI and Motor Func-
tion Measure [26]. Similarly to previous longitudinal co-
horts in neuromuscular diseases [32], we showed that
the 6MWD was a good outcome parameter in LOPD.
Limitations and strengths of the study
Because of the retrospective nature of the study, there
were some missing data for different outcome measures,
the patient population was heterogeneous concerning
current age and disease duration since data were col-
lected from a fixed timeframe (2010–2017), and there
was no comparison with an untreated control group
since most data in the study were obtained from treated
LOPD patients.
Despite these shortcomings, we performed a detailed
clinical, imaging and genetic characterisation of all Bel-
gian LOPD patients and identified useful longitudinal
outcome measures in LOPD that can be applied in fu-
ture clinical trials.
Conclusions
Awareness on LOPD should even be further increased,
as we found a long diagnostic delay as described in other
populations. As ERT is more effective in the beginning
of the disease, early start of therapy is important. In the
follow-up of patients, physical outcome measures and
patient reported outcome measures are needed, as the
relation between these two is not straightforward. The
6MWD, but not the ActivLim score, is a sensitive out-
come measure to follow up LOPD patients.
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